Archive \ Volume.4 2013 Issue 4

FORMULATION DEVELOPMENT OF SELF NANOEMULSIFYING DRUG DELIVERY SYSTEM (SNEDDS) OF CELECOXIB FOR IMPROVEMENT OF ORAL BIOAVAILABILITY

Gurjeet Kaur , Pankaj Chandel and S.L. Harikumar
Abstract

Celecoxib is a hydrophobic and highly permeable drug which belongs to class II of biopharmaceutics classification system (BCS). Low aqueous solubility of celecoxib leads to high variability in absorption after oral administration. The present study was carried out for the formulation development of celecoxib loaded self nanoemulsifying drug delivery system (SNEDDS) with the aim of enhancement of oral bioavailability. The SNEDDS formulation was optimized using pseudo-ternary phase diagram composed of capryol 90, cremophor RH 40 and propylene glycol. Six formulations (F1, F2, F3, F4, F5 and F6) were developed with varying concentration of oil, surfactant and co-surfactant by sonication technique. The self nano-emulsifying drug delivery system of celecoxib was characterized for content uniformity, particle size, poly dispersity index, viscosity determination and robustness of dilution, drug loading efficiency and shape of globules, thermodynamic stability and self emulsification efficiency. In vitro dissolution and in vitro diffusion studies were also carried out to get final optimized formulation. The optimized celecoxib SNEDDS (F6) found to contain surfactant content less than 30% and yielded nanoemulsion of mean droplet size 169.4nm, which was not affected by the pH of dilution media. The zeta potential of the optimized SNEDDS (F6) found to be -32.9 mV. The drug loading efficiency of the formulation F6 was high at 98.98%. The developed celecoxib loaded SNEDDS formulation exhibited a complete in vitro drug release in 1hr as compared with the plain drug. Thus, the self nanoemulsifying drug delivery system (SNEDDS) using celecoxib as model drug found to achieve effective therapeutic concentration and intended to provide relief from pain associated with inflammation by single dose administration as compared to conventional tablets as well as prevent the cardiac risks due to lower dose size.